SHR1459

DRUG4 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

Conditions

Healthy Adult SubjectsHealthy Subjects, Drug-drug Interaction, Pharmacokinetics, SHR1459Healthy VolunteersMature B Cell Neoplasms

Phase 1

Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor

Jiangsu HengRui Medicine Co., Ltd.Mature B Cell Neoplasms

Start: 2018-02-06End: 2024-12-30Updated: 2022-11-14

Safety, Tolerability and PK/PD of SHR1459 in Healthy Volunteers

Jiangsu HengRui Medicine Co., Ltd.Healthy Volunteers

Start: 2018-09-01End: 2019-03-01Target: 30Updated: 2018-09-12

A Bioavailability Study of SHR1459 on Healthy Chinese Volunteers

CompletedNCT04395053

Jiangsu HengRui Medicine Co., Ltd.Healthy Adult Subjects

Start: 2020-06-28End: 2020-08-01Updated: 2022-11-07

Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)

CompletedNCT04649723

Jiangsu HengRui Medicine Co., Ltd.Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, SHR1459

Start: 2020-11-24End: 2020-12-14Updated: 2021-01-11